Výsledky vyhledávání - "Virginie, Adam"

Akademický článek

A mixed method feasibility and acceptability study of a flexible intervention based on acceptance and commitment therapy for patients with cancer

Autor: François Bourgognon, Denise Bechet, Cécile Huin-Schohn, Aurélia Strelow, Laëtitia Demarche, Mireille Guillou, Virginie Adam, Estelle Fall, Abdou Yacoubou Omorou

Publikováno v: Frontiers in Psychology, Vol 15 (2024)

ProposeThis study aimed to propose an innovative, open, and circular program that combines acceptance and commitment therapy (ACT) and mindfulness practices. We assessed its feasibility, acceptability, and first signs of its effect on psychological w

Externí odkaz: https://doaj.org/article/ce39bd0382214fc8a593405f8317e752

Zobrazit plný text záznamu

Akademický článek

APP family member dimeric complexes are formed predominantly in synaptic compartments

Autor: Sandra Schilling, Alexander August, Mathieu Meleux, Carolin Conradt, Luisa M. Tremmel, Sandra Teigler, Virginie Adam, Ulrike C. Müller, Edward H. Koo, Stefan Kins, Simone Eggert

Publikováno v: Cell & Bioscience, Vol 13, Iss 1, Pp 1-24 (2023)

Abstract Background The amyloid precursor protein (APP), a key player in Alzheimer’s disease (AD), is part of a larger gene family, including the APP like proteins APLP1 and APLP2. They share similar structures, form homo- and heterotypic dimers an

Externí odkaz: https://doaj.org/article/a809ffebfcb1404d87c26c6dbb1a7647

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Conversational hypnosis versus standard of care to reduce anxiety in patients undergoing marker placement under radiographic control prior to breast cancer surgery: A randomized, multicenter trial

Autor: Lydie Lemoine, Virginie Adam, Xavier Galus, Pascale Siles, Agnès Coulon, Jeannette Grenier-Desforges, Joseph Orabona, Isabelle Kergastel, Pierre Wagner, Julia Salleron, Priscillia Tosti, Cécile Huin-Schohn, Jean-Louis Merlin, Rémi Etienne, Philippe Henrot

Publikováno v: Frontiers in Psychology, Vol 13 (2022)

BackgroundSurgery is a cornerstone of breast cancer management. Prior to surgery, a wire marker is placed at the site of the tumor, to enable the surgeon to accurately localize the lesion during later surgery. This procedure can generate considerable

Externí odkaz: https://doaj.org/article/83d284888d8b4f8f8a5841b249eda9f6

Zobrazit plný text záznamu

A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer

Autor: Jose Alejandro Pérez-Fidalgo, Carmen Criscitiello, Eva Carrasco, Meredith M Regan, Angelo Di Leo, Karin Ribi, Virginie Adam, Philippe L Bedard

Publikováno v: Future Oncology. 18:2339-2349

ALPHABET is a randomized phase III trial assessing alpelisib + trastuzumab with or without fulvestrant in previously treated HER2-positive PIK3CA-mutated advanced breast cancer. Patients will be included in two cohorts according to hormone receptor (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2e194ca39bad0ec009fc9f5962a39157
https://doi.org/10.2217/fon-2022-0045

Zobrazit plný text záznamu

Data from Improved Potency and Selectivity of an Oncolytic E1ACR2 and E1B19K Deleted Adenoviral Mutant in Prostate and Pancreatic Cancers

Autor: Gunnel Halldén, Nick R. Lemoine, Celina Costas, Katrina Sweeney, Virginie Adam, Eva Yanover, Daniel Öberg

Purpose: Replication-selective oncolytic adenoviruses are a promising class of tumor-targeting agents with proven safety in hundreds of patients. However, clinical responses have been limited and viral mutants with higher potency are needed. Here, we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62986b4e64218274d34d45126f478a11
https://doi.org/10.1158/1078-0432.c.6517690.v1

Zobrazit plný text záznamu

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: The EORTC 1307-BCG/ BIG5–13/TESARO PR-30–50–10-C BRAVO Study

Publikováno v: Clinical cancer research, 27 (20
Clin Cancer Res
2021, ' Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study ', Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-21-0310

Purpose: To investigate the activity of niraparib in patients with germline-mutated BRCA1/2 (gBRCAm) advanced breast cancer. Patients and Methods: BRAVO was a randomized, open-label phase III trial. Eligible patients had gBRCAm and HER2-negative adva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a1bfde4ac52e52c38e495f34c523cc
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/333689

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání